Cover Image
Market Research Report

COVID-19 Pipelines - Cell Therapies, Diagnostics, Treatments, & Vaccines

Published by BIOINFORMANT WORLDWIDE, LLC Product code 940594
Published Content info 269 Pages
Delivery time: 1-2 business days
Price
Back to Top
COVID-19 Pipelines - Cell Therapies, Diagnostics, Treatments, & Vaccines
Published: June 8, 2020 Content info: 269 Pages
Description

This comprehensive report provides coverage of the rapidly evolving pandemic, with an emphasis on the emerging role of cell therapies in the prevention and management of the COVID-19.

While there is not yet an approved treatment for COVID-19, the scientific, medical and regulatory agencies are making heroic efforts to bring out new medicines. Numerous COVID-19 product categories have emerged, including vaccines, antibodies, antivirals, repurposed drugs, RNA-based drugs, and cell-based therapies, as well as other approaches, such as enzymes, peptides and glycoproteins. This report explores each of these product development categories in detail, presenting the products under development and timelines for them to come to market. Special attention is given to the critical role of cell-based therapies in management of the global pandemic.

Thousands of scientific articles have been published electronically or in print since the outbreak of COVID-19 began in late 2019. Patent activity around COVID-19 is surging, with many companies securing intellectual property (IP) related to the development of COVID-19 therapeutics. To a lesser degree, companies are securing IP around vaccines, diagnostic agents, and methods. This report reveals rates of COVID-19 scientific publications and presents a global breakdown of COVID-19 patent activity that includes patent type, sponsoring organization, and method of action.

Furthermore, new diagnostic tests for COVID-19 are emerging as an essential tool to track the spread of the disease, as the World Health Organization (WHO) is urging health agencies worldwide to make testing for the virus a top priority. As of May 20, 2020, the FDA granted Emergency Use Authorization (EUA) for 58 viral RNA-based tests, ten antibody-based tests, one antigen-based test and one home collection kit.

To accelerate the development of therapies against COVID-19, the repurposing of existing drugs is being explored by numerous market competitors. For example, Barcitinib is being explored because of its anti-inflammatory effect and possible ability to reduce viral entry. A specific dose of the anti-HIV combination, Lopinavir-Nitonavir, is now in clinical trials with Arbidol or Ribavirin. Remdesivir, developed by Gilead Sciences, was earlier tested in patients with Ebola virus and has shown promise in animal models for MERS and SARS. Remdesivir has reached Phase III in the U.S. and China.

Favipiravir, a purine nucleoside leading to inaccurate viral RNA synthesis, was previously developed by Toyama Chemical of Japan, and has now been approved for a clinical trial as a drug for the treatment of COVID-19. Chloroquine has shown itself to be effective in treating COVID-19 in China. Dozens of companies are rushing vaccine development and proceeding toward clinical trials. As select examples, the U.S. NIH initiated a Phase I trial in Seattle evaluating an investigational vaccine (mRNA-1273) created by NIAID scientists and their collaborators at Moderna, Inc. Sanofi and Regeneron launched a Phase II/II trial in New York evaluating the IL-6 targeted Kevzara. Inovio Pharmaceuticals is advancing its vaccine into human trials within the U.S. and intends to produce one million doses of it by the end of the year.

Globally, the healthcare industry is using every weapon in its armory to suppress the threat from the virus, including the use of living therapies such as natural killer (NK) cells, T-cells, stem cells and exosomes. While many novel approaches are being investigated, stem cells - mesenchymal stem cells (MSCs) in particular - are showing intriguing potential for the treatment of COVID-19.

MSCs are receiving attention because past studies have found the secretions from MSCs to be effective at treating inflammation and cytokine storms. From early-stage studies, it appears that MSC may exert beneficial effects, potentially by improving the lung microenvironment, inhibiting immune system over-activation, promoting tissue repair, protecting lung alveoli epithelial cells, preventing pulmonary fibrosis, or improving lung function.

Already, Athersys, Inc. has reported positive outcomes in other studies using MSCs for treating respiratory disease, and Mesoblast's Remestemcel-L has proved to be effective in treating advanced respiratory distress. Athersys and Mesoblast are enrolling for 300 and 400 patient trials, respectively - two of the largest stem cell trials to date against COVID-19. In total, at least 26 companies are exploring cell therapy products against COVID-19 and its complications.

In the recent months, there has been a flurry of activity within the clinical trial sector. When all trial types are considered, there are over 400 studies exploring approaches to diagnosing, treating or preventing COVID-19. ClinicalTrials.gov has also reported at least 15 trials leveraging stem cells against COVID-19.

COVID-19 Market Trends

The aim of this report is to gather existing research on COVID-19, reveal key insights and position the reader to identify emerging market opportunities related to the Coronavirus pandemic. It provides comprehensive coverage of the outbreak, highlights global competitors involved in the fight against COVID-19, and presents product development pipelines, diagnostic testing approaches, vaccine development programs, regulatory approvals, and importantly, trend rate data for COVID-19 scientific publications, patents, and clinical trials on a worldwide basis.

With the rapidly developing nature of this global pandemic, you don't have the time to do the research. Claim this global strategic report to become immediately informed, without sacrificing hours of unnecessary research or lacking awareness of critical COVID-19 events.

Table of Contents

TABLE OF CONTENTS

1. REPORT OVERVIEW

  • 1.1. Statement of the Report
  • 1.2. Executive Summary
  • 1.3. Introduction

2. CORONAVIRUS: STRUCTURE, INFECTION, REPLICATION, SYMPTOMS

  • 2.1. Start of the Outbreak
    • 2.1.1. Structure of COVID-19
    • 2.1.2. Structure of COVID-19's Spike Protein and Enzymes
    • 2.1.3. The Details of COVID-19's RNA-dependent RNA polymerase (RdRp)
    • 2.1.4. Crystal Structure of COVID-19 Virus's Protease Enzyme
    • 2.1.5. Structure of COVID-19 virus's Spike Protein
    • 2.1.6. The Binding of a Patients Antibody with COVID-19 Virus's Spike Protein
    • 2.1.7. Potential Binding Sites of Human Protein Complex (CUL2ZYG11B)
    • 2.1.8. The Binding of Coronavirus to Target Protein on Human Cell
    • 2.1.9. The Cause of COVID-19 Virus's Rapid Spread
  • 2.2. The Symptoms of COVID-19
  • 2.3. Progression of COVID-19
  • 2.4. The Incubation Period for COVID-19
  • 2.5. Duration of the Disease
  • 2.6. Case Fatality Rate
    • 2.6.1. CFR for COVID-19 by Age
    • 2.6.2. CFR for COVID-19 by Pre-Existing Health Issues
    • 2.6.3. Case Fatality Rate for Select Countries and the World
  • 2.7. Modes of COVID-19 Transmission
  • 2.8. Clinical Case Management

3. GLOBAL STATISTICS ON COVID-19

  • 3.1. The Steady Increase in Global Number of Confirmed Cases
    • 3.1.1. Steep Increase in COVID-19 Deaths
    • 3.1.2. Number of COVID-19 Confirmed Cases by Geography as of May 21, 2020
    • 3.1.3. Number of COVID-19 Deaths by Geography as of May 21, 2020
    • 3.1.4. China Returning to Normalcy
    • 3.1.5. COVID-19 Deaths in China
  • 3.2. Top Five Most Affected Countries
    • 3.2.1. COVID-19 in the U.S.
      • 3.2.1.1. COVID-19 Deaths in the U.S.
    • 3.2.2. COVID-19 Confirmed Cases in U.K.
      • 3.2.2.1. COVID-19 Deaths in U.K.
    • 3.2.3. COVID-19 Confirmed Cases in Italy
      • 3.2.3.1. COVID-19 Deaths in Italy
    • 3.2.4. COVID-19 Confirmed Cases in France
      • 3.2.4.1. COVID-19 Deaths in France
    • 3.2.5. COVID-19 Confirmed Cases in Spain
  • 3.3. COVID-19 Deaths Compared with Deaths Due to Other Diseases
  • 3.4. The Ebb and Flow of COVID-19 Cases
  • 3.5. Africa Spared the Worst of the Pandemic
  • 3.6. Number of Laboratory Tests Conducted by Select Countries
  • 3.7. Top Four Countries with Number of COVID-Tests

4. FUNDING FOR COVID-19 RESEARCH

  • 4.1. Contributions to WHO for COVID-19 Appeal
    • 4.1.1. Contingency Fund for Emergencies
  • 4.2. National Institutes of Health (NIH) Funding for COVID-19 Research
  • 4.3. Funding for COVID-19 Research from U.S. Stimulus Bill

5. PUBLISHED SCIENTIFIC PAPERS ON COVID-19

  • 5.1. Published Papers by Category
  • 5.2. Notable Journal Articles

6. PATENTS OF SARS AND MERS WITH POSSIBLE RELEVANCE TO COVID-19

  • 6.1. Types of SARS and MERS Patents
  • 6.2. Key Proteins Described in the Patents and their Roles in Viral Infection
  • 6.3. Patents and Potential Drug Candidates Related to Key Protein Targets
  • 6.4. Patents of Existing Drugs with Potential Applications for COVID-19
  • 6.5. Selected Patents Related to Small Molecule Drug Candidates
    • 6.5.1. Compounds with Potential Effects on Key Proteins of COVID-19
    • 6.5.2. Small Molecules Identified by Structure Similarity and Therapeutic Usage
  • 6.6. Distributions of Biologics Patents Related to SARS and MERS
    • 6.6.1. Patents of SARS Antibodies
  • 6.7. Distribution of Patents of Vaccines Related to SARS/MERS
  • 6.8. Distribution of RNAi Patents related to SARS/MERS

7. CLINICAL TRIALS LANDSCAPE FOR COVID-19

  • 7.1. COVID-19 Clinical Trials by Country/Region
  • 7.2. Clinical Trials by Study Type
    • 7.2.1. Types of Interventions in the Ongoing COVID-19 Clinical Trials
      • 7.2.1.1. Proposed Pharmacological Interventions in COVID-19 Clinical Trials
      • 7.2.1.2. ATMPs under Investigation in COVID-19 Trials
  • 7.3. COVID-19 Clinical Trials by Stage of Development
    • 7.3.4. COVID-19 Clinical Trials by Funding Type
      • 7.3.4.1. Industry-Sponsored Clinical Trials against COVID-19
  • 7.4. Upcoming Readouts from Ongoing COVID-19 Clinical Trials

8. COVID-19'S NEGATIVE/POSIVE IMPACTS ON HEALTHCARE INDUSTRY

  • 8.1. Negative Impacts
    • 8.1.1. Disruption of Big Clinical Trials by COVID-19 Pandemic
    • 8.1.2. 15-Fold Increase in Clinical Trial Suspensions
    • 8.1.3. Specific Examples of Clinical Trials Threatened by COVID-19
    • 8.1.4. Delayed Readouts due to COVID-19
    • 8.1.5. Shortages of Patients for Phase III due to COVID-19
    • 8.1.6. Most Hit Pivotal Trials
    • 8.1.7. Threat to Trials of Near-Term Blockbusters
    • 8.1.8. COVID-19's Deleterious Effects on Elective Procedures
    • 8.1.9. COVID-19 Infected Cardiovascular Companies
    • 8.1.10. Delayed Acquisitions due to COVID-19
    • 8.1.11. Stalling of Biotech Flotations by COVID-19
    • 8.1.12. Financial Damages to the Pharmaceutical Industry due to COVID-19
  • 8.2. Positive Impacts
    • 8.2.1. Sizeable Opportunities for Some Collaborations
    • 8.2.2. COVID-19 Market Movers
    • 8.2.3. COVID-19 Events that Pushed the Share Prices up
      • 8.2.3.1. Johnson & Johnson
      • 8.2.3.2. Gilead Sciences
      • 8.2.3.3. Roche
      • 8.2.3.4. Sanofi
      • 8.2.3.5. BioNTech
      • 8.2.3.6. Moderna
      • 8.2.3.7. Vir Biotechnology
      • 8.2.3.8. Takeda
      • 8.2.3.9. CytoDyn
    • 8.2.4. COVID-19-Related Stock Risers

9. MEDICINES IN DEVELOPMENT FOR COVID-19

  • 9.1. The First Medicine to Reach the Market
    • 9.1.1. Spectrum of Drugs
    • 9.1.2. Difficulties in Making a Drug in Time
      • 9.1.2.1. Bargain Search
      • 9.1.2.2. Three Stages in Development
      • 9.1.2.3. Massive Demand
    • 9.1.3. Generic for Remdesivir
    • 9.1.4. Concern about Access to COVID-19 Medicine
  • 9.2. FDA's CTAP to Accelerate COVID-19 Drug Development
    • 9.2.1. CTAP's Activities in a Snapshot

10. EMERGING VACCINE TREATMENTS FOR COVID-19

  • 10.1. Protein Sub-Unit Vaccines in Development against COVID-19
  • 10.2. RNA-Based Vaccines
  • 10.3. Non-Replicating Viral Vector Vaccines
  • 10.4. DNA Vaccines in Development for COVID-19
  • 10.5. Inactivated Virus Vaccines in Development for COVID-19
  • 10.6. Virus-like Particle Vaccines in Development for COVID-19
  • 10.7. The Nearest Vaccine
  • 10.8. Additional COVID-19 Vaccine Projects
  • 10.9. CEPI's Call for Vaccine Fund
  • 10.10. Clinical Trial Costs for Developing a Viral Vaccine
  • 10.11. The Usual Pattern of Revenue Generation by Viral Vaccines
    • 10.11.1. Historical Sales of Vaccines for Previous Pandemics
    • 10.11.2. Historic Sales of H1N1 Influenza Vaccines
  • 10.12. Recent Vaccine Collaborations
  • 10.13. Companies Capable of Producing Vaccines on a Global Scale
  • 10.14. Big Pharma in COVID-19 Vaccines

11. ANTIBODY THERAPIES IN DEVELOPMENT FOR COVID-19

12. ANTIVIRAL DRUGS IN DEVELOPMENT FOR COVID-19

  • 12.1. Estimated Cost of COVID-19 Antiviral Therapeutic Development
  • 12.2. A Competitor for Gilead
  • 12.3. Remdesivir: The First to Reach the Market
    • 12.3.1. Hints of a Hope from Remdesivir Results
    • 12.3.2. Interim Data for Remdesivir
    • 12.3.3. Sales Forecast for Remdesivir
  • 12.4. Structure of Remdesivir
    • 12.4.1. Mechanism of Action of Remdesivir
  • 12.5. Additional COVID-19 Therapeutic Projects

13. REPURPOSED DRUG CANDIDATES AGAINST COVID-19

14. CELL-BASED THERAPIES IN DEVELOPMENT FOR COVID-19

  • 14.1. Brief Descriptions of Stem Cell-Based Clinical Trials for COVID-19
    • 14.1.1. NCT04313322 (Stem Cells Arabia)
    • 14.1.2. NCT04366063 (Royan Institute)
    • 14.1.3. NCT04252118 (Beijing 302 Hospital)
    • 14.1.4. NCT04346368 (Guangzhou Institute of Respiratory Disease)
    • 14.1.5. NCT04331613 (Chinese Academy of Sciences)
    • 14.1.6. NCT04390139 (Banc de Sang i Teixits)
    • 14.1.7. NCT04355728 (Camillo Ricordi)
    • 14.1.8. NCT04299152 (Tianhe Stem Cell Biotechnologies, Inc)
    • 14.1.9. NCT04269525 (ZhiYong Peng)
    • 14.1.10. NCT04390152 (BioXcellerator)
    • 14.1.12. NCT04362189 (Hope Biosciences)
    • 14.1.13. NCT04371393 (Icahn School of Medicine/Mesoblast, Inc)
    • 14.1.14. NCT04365101 (Celularity Incorporated)
    • 14.1.15. NCT04367077 (Athersys, Inc)
  • 14.2. MSCs: The Most Suitable Cells to be used Against COVID-19

15. MEDICAL DEVICES IN DEVELOPMENT FOR COVID-19

  • 15.1. The Scramble for Mechanical Ventilators
  • 15.2. Ventilator Shortages

16. COMMERCIALLY AVAILABLE DIAGNOSTICS FOR COVID-19

  • 16.1. PCR Tests (Viral RNA Tests)
  • 16.2. Serology Tests (Antibody Tests)
  • 16.3. Antigen Tests
    • 16.3.1. Number of EUAs Granted to Viral RNA Tests and Antibody Tests
    • 16.3.2. Specific Issues with Antibody Tests
    • 16.3.3. Roche's Antibody Test: Maximum Sensitivity and Specificity
  • 16.4. The First COVID-19 Antigen Test
  • 16.5. At-Home COVID-19 Sample Collection Kit
  • 16.6. Top Ten COVID-19 Diagnostic Companies
  • 16.7. The Deluge of Testing Options

17. MARKET ANALYSIS

  • 17.1. Global COVID-19 Vaccine Market
  • 17.2. Global Market for Antiviral Drugs against COVID-19
  • 17.3. Global Market for Diagnostic Tests for COVID-19
    • 17.3.1. Global Market for COVID-19 Testing Kits by Technology
  • 17.4. COVID-19 Addressable Personal Protection Equipment (PPE) Market
  • 17.5. Estimated COVID-19 Addressable Critical Care Device Market
  • 17.6. Global Market for "Other" COVID-19-Related Medical Supplies
    • 17.6.1. Market Shares of Face Masks by Type of Material
    • 17.6.2. Global Market Share for Hand Sanitizers by Type
  • 17.7. Global COVID-19 Treatment Market

18. CELL THERAPY COMPANIES JOINING FORCES AGAINST COVID-19

  • 18.1. Aspire Health Science
    • 18.1.1. Filing of Investigational New Drug
    • 18.1.2. ACT-20
  • 18.2. Athersys, Inc.
    • 18.2.1. MultiStem
    • 18.2.2. MultiStem for COVID-19
    • 18.2.3. MACOVIA Study
  • 18.3. AlloVir
    • 18.3.1. Technology
  • 18.4. Bonus BioGroup, Ltd.
    • 18.4.1. MesenCure
  • 18.5. Caladrius Biosciences
    • 18.5.1. CLBS12
    • 18.5.2. CLBS14
    • 18.5.3. CLBS16
    • 18.5.4. CLBS119 for COVID-19
    • 18.5.5. CLBS03
  • 18.6. Capricor Therapeutics
    • 18.6.1. CAP-1002
    • 18.6.2. Exosomes
    • 18.6.3. CAP-1002 for COVID-19
  • 18.7. Celularity
    • 18.7.1. IMPACT Platform
    • 18.7.2. Collaboration with United Therapeutics
  • 18.8. Celltex Therapeutics Corporation
    • 18.8.1. FDA Approval Sought
  • 18.9. Citius Pharmaceuticals, Inc.
    • 18.9.1. License Agreement with Novellus, Inc.
  • 18.10. Cynata Therapeutics
    • 18.10.1. Cynata and COVID-19
  • 18.11. FibroGenesis
    • 18.11.1. PneumoBlast
    • 18.11.2. Patent for COVID-19 Induced ARDS
  • 18.12. GC LabCell
  • 18.13. Global Institute of Stem Cell Therapy and Research (GIOSTAR)
    • 18.13.1. FDA Approval for COVID-19 Trial
  • 18.14. Healios KK
    • 18.14.1. New Treatment for ARDS
  • 18.15. Hope Biosciences
    • 18.15.1. Stem Cell Banking for Newborns
    • 18.15.2. Stem Cell Banking for Adults
    • 18.15.3. FDA Clearance for Phase II Trial of COVID-19
  • 18.16. Kimera Labs, Inc.
    • 18.16.1. Products
      • 18.16.1.1. Exosomes: A Possible Therapy for COVID-19
  • 18.17. Lattice Biologics, Ltd.
    • 18.17.1. Products
    • 18.17.2. Clinical Trial
  • 18.18. Lineage Cell Therapeutics, Inc.
    • 18.18.1. Cell Therapy Programs
      • 18.18.1.1. OpRegen
      • 18.18.1.2. OPC1
      • 18.18.1.3. VAC2
      • 18.18.1.4. COVID-19 Vaccine Development
  • 18.19. Mesoblast, Ltd.
    • 18.19.1. Remestemcel-L
    • 18.19.2. Phase II/III Trial of Remestemcel-L
  • 18.20. NantKwest, Inc.
    • 18.20.1. NantKwest and ImmunityBio against COVID-19
  • 18.21. Orbsen Therapeutics
    • 18.21.1. Orbsen's ORBCEL for COVID-19
  • 18.22. Organicell
    • 18.22.1. Organicell Flow
    • 18.22.2. Organicell Flow for COVID-19
  • 18.23. Pluristem Therapeutics, Inc.
    • 18.23.1. Pluristem's Drug Development Alliance against COVID-19
  • 18.24. Tianhe Stem Cell Biotechnologies, Inc.
  • 18.25. The Cure Alliance
    • 18.25.1. Cure Alliance's Alliance with University of Miami against COVID-19
  • 18.26. Vitro Biopharma
    • 18.26.1. Cell Therapy for COVID-19

19. OTHER COMPANIES/INSTITUTIONS SPONSORING TRIALS FOR COVID-19

  • 19.1. AlloVir and Baylor College of Medicine
  • 19.2. Biostar Stem Cell Research Institute
  • 19.3. CAR-T (Shanghai) Biotechnology, Co., Ltd
  • 19.4. Orgenesis' Cell-Based Vaccine
  • 19.5. Peking University
  • 19.6. REMSTEM's Phase I/IIa for COVID-19
  • 19.7. University of Miami-COVID-19 Research Programs
  • 19.8. Wuhan Hamilton Biotechnology

APPENDIX

  • Appendix 1: History of Pandemics
  • Appendix 1.1: A Timeline of Historical Pandemics
  • Appendix 1.2: Importing Disease
  • Appendix 1.3: Tracking Infectiousness
  • Appendix 1.4: Urbanization and Spread of Pandemics
  • Appendix 2: Global Pandemic Preparedness by Country
  • Appendix 3: The Math behind Social Distancing
  • Appendix 3.1: Effectiveness of Social Distancing
  • Appendix 4: Recent COVID-19 News in Brief
  • Appendix 4.1: Multiple Clinical Trials Test NO Gas for COVID-19
  • Appendix 4.2: U.S. Signed a Huge COVID-19 Drug Contract with Start-Up
  • Appendix 4.3: Cursory Glance at First COVID-19 Vaccine Data
  • Appendix 4.4: CEPI Grants $384 Million to Novavax's COVID-19 Vaccine
  • Appendix 4.5: Adenoviral Vector Vaccines are the Front-Runners against COVID-19
  • Appendix 4.6: The Most Effective Masks for COVID-19
  • Appendix 4.7: FDA Approval for CRISPR-Based COVID-19 Diagnostic
  • Appendix 4.8: The Antiviral EIDD-2801 to Aim at COVID-19
  • Appendix 4.9: A Loose Alliance of Competitors against COVID-19
  • Appendix 4.10: About 69 Repurposed Drugs Can Block the Replication of COVID-19
  • Appendix 4.11: Lonza to make 1 Billion Doses of Gilead's Remdesivir
  • Appendix 4.12: Merck KGaA to Ramp up Viral Vaccine Manufacturing
  • Appendix 4.13: DuPont, FeDEx and U.S. Government Teamed Up for PPE
  • Appendix 4.14: Fujifilm Tests Favipiravir against COVID-19
  • Appendix 4.15: Resolution to Produce I Million Swabs per Week
  • Appendix 4.16: BioNTech is in the Race for Vaccine

INDEX OF FIGURES

  • FIGURE 2.1: Diagrammatic Cross Sectional View of COVID-19
  • FIGURE 2.2: Structure of the Spike Protein and Enzymes of COVID-19
  • FIGURE 2.3: COVID-19 Virus's RdRp with nsp12 and nsp7
  • FIGURE 2.4: Schematic Representation of a Protease Dimer bound with two Inhibitors
  • FIGURE 2.5: The 3D Structure of the Spike Protein
  • FIGURE 2.6: The Antibody CR3022 Binding with the Spike Protein
  • FIGURE 2.7: Human Protein Complex Showing the Potential Binding Sites for the Virus
  • FIGURE 2.8: The Binding of Coronavirus to Target Protein on Human Cell
  • FIGURE 2.9: The Crystal Structure of the Enzyme ACE2
  • FIGURE 2.10: The Symptoms of COVID-19
  • FIGURE 2.11: CFR for COVID-19 in China over Time and Location
  • FIGURE 2.12: CFR for COVID-19 by Age
  • FIGURE 2.13: CFR for COVID-19 by Pre-Existing Health Issues
  • FIGURE 2.14: Case Fatality Rate for Select Countries and the World
  • FIGURE 3.1: The Steady Increase in Global Number of Confirmed Cases
  • FIGURE 3.2: Steep Increase in COVID-19 Deaths
  • FIGURE 3.3: Number of COVID-19 Confirmed Cases by Geography as of May 21, 2020
  • FIGURE 3.4: Number of COVID-19 Deaths by Geography as of May 21, 2020
  • FIGURE 3.5: Number of COVID-19 Confirmed Cases in China, Jan-22 to May-21, 2020
  • FIGURE 3.6: COVID-19 Deaths in China
  • FIGURE 3.7: COVID-19 in the U.S.
  • FIGURE 3.8: COVID-19 Deaths in the U.S.
  • FIGURE 3.9: COVID-19 Confirmed Cases in U.K.
  • FIGURE 3.10: COVID-19 Deaths in U.K.
  • FIGURE 3.11: COVID-19 Confirmed Cases in Italy
  • FIGURE 3.12: COVID-19 Deaths in Italy
  • FIGURE 3.13: COVID-19 Confirmed Cases in France
  • FIGURE 3.14: COVID-19 Deaths in France
  • FIGURE 3.15: COVID-19 Confirmed Cases in Spain
  • FIGURE 3.16: Number of COVID-19 Confirmed Cases in Africa
  • FIGURE 3.17: Top Four Countries in COVID-19 Testing
  • FIGURE 4.1: WHO's Estimated Fund to be raised in Response to COVID-19
  • FIGURE 5.1: Number of COVID-19-Related Scientific Papers
  • FIGURE 6.1: Distribution of Patents Related to SARS and MERS
  • FIGURE 6.2: Distributions of Biologics Patents Related to SARS and MERS
  • FIGURE 6.3: Distribution of Patents of Vaccines Related to SARS/MERS
  • FIGURE 7.1: Percent Share of Clinical Trials for COVID-19 by Region
  • FIGURE 7.2: Number of Clinical Trials for COVID-19 by Study Type
  • FIGURE 7.3: Percent Shares of Interventional Types in COVID-19 Clinical Trials
  • FIGURE 7.4: COVID-19 Clinical Trials by Stage of Development
  • FIGURE 7.5: COVID-19 Clinical Studies by Funding Type
  • FIGURE 8.1: Clinical Trial Terminations/Withdrawals/Suspensions
  • FIGURE 8.2: Biotech IPOs by quarter
  • FIGURE 8.3: Market Cap Gain and Loss by Size Bracket between Q4 2019 and Q1 2020
  • FIGURE 8.4: Key COVID-19 Market Movers as of April 1, 2020
  • FIGURE 9.1: Percent Share of Emerging Treatments and Vaccines for COVID-19
  • FIGURE 10.1: Percent Share of Different Types of Vaccines in Development
  • FIGURE 10.2: Pattern of Revenue Generation by Flu Vaccine of GlaxoSmithKline
  • FIGURE 10.3: Historic Sales of H5N1 Vaccines
  • FIGURE 10.4: Historic Sales of H1N1 Influenza Vaccines
  • FIGURE 10.5: World's Biggest Vaccine Makers and their Vaccine Sales
  • FIGURE 12.1: Sales of Roche's Antiviral Tamiflu
  • FIGURE 12.2: Consensus Sales Forecast for Remdesivir
  • FIGURE 12.3: Structure of Remdesivir
  • FIGURE 12.4: Mechanism of Action of Remdesivir
  • FIGURE 16.1: EUAs Granted to COVID-19 Tests
  • FIGURE 16.2: EUA for Antigen Test and Home Test Kits
  • FIGURE 17.1: Estimated Global Market for COVID-19 Vaccines, 2020-2027
  • FIGURE 17.2: Global Market for COVID-19 Drugs, 2020-2027
  • FIGURE 17.3: Global Market for COVID-19 Testing Kits by Geography, 2020-2027
  • FIGURE 17.4: Global Market for COVID-19 Testing Kits by Technology, 2020-2027
  • FIGURE 17.5: COVID-19 Impacted Market for PPE Products, 2020-2027
  • FIGURE 17.6: Estimated COVID-19 Addressable Critical Care Device Market, 2020-2027
  • FIGURE 17.7: Global Market for Face Masks, 2020-2027
  • FIGURE 17.8: Market Shares of Face Masks by Type of Material
  • FIGURE 17.9: Global Market Share for Hand Sanitizers by Type
  • FIGURE 17.10: Global Market for COVID-19 Treatment, 2020-2027
  • FIGURE 18.1: Tianhe's Stem Cell Educator Therapy
  • FIGURE App. 3.1: Social Distancing and Final Illness Attacking Rate

INDEX OF TABLES

  • TABLE 3.1: Total Confirmed Cases and Deaths from January 21 to May 21
  • TABLE 3.1: (CONTINUED)
  • TABLE 3.1: (CONTINUED)
  • TABLE 3.1: (CONTINUED)
  • TABLE 3.2: Average Death per day due to Various Diseases
  • TABLE 3.3: Countries with Confirmed New Cases Decreasing/Increasing as of May 12
  • TABLE 3.4: Number of COVID-19 Confirmed Cases in Africa
  • TABLE 3.5: COVID-19 Tests Performed per 1,000 people by Select Country
  • TABLE 3.5: (CONTINUED)
  • TABLE 3.6: Top Four Countries in COVID-19 Testing
  • TABLE 4.1: Contributions to WHO for COVID-19 as of May 20, 2020
  • TABLE 4.1: (CONTINUED)
  • TABLE 4.2: CFE's Allocations in 2020
  • TABLE 4.3: NIH Funding for COVID-19 Research as of May 27, 2020
  • TABLE 4.3: (CONTINUED)
  • TABLE 4.3: (CONTINUED)
  • TABLE 4.3: (CONTINUED)
  • TABLE 4.3: (CONTINUED)
  • TABLE 4.4: COVID-19 Research Fund through CARES Act in the U.S.
  • TABLE 5.1: Number of Published Papers by Category as of May 24, 2024
  • TABLE 5.2: Notable Journal Articles
  • TABLE 6.1: Key Proteins and their Roles in Viral Infection
  • TABLE 6.2: Patents and Potential Drug Candidates Related to Key Protein Targets
  • TABLE 6.3: Existing Drugs with Potential Applications for COVID-19
  • TABLE 6.4: Selected Patents Related to Small Molecule Drug Candidates
  • TABLE 6.5: Select Small Molecule Compounds in R&D to Treat COVID-19
  • TABLE 6.6: Small Molecules Identified by Structure Similarity and Therapeutic Usage
  • TABLE 6.7: Patents on Developing Therapeutic Antibodies against SARS
  • TABLE 6.7: (CONTINUED)
  • TABLE 6.7: (CONTINUED)
  • TABLE 6.7: (CONTINUED)
  • TABLE 6.8: Distribution of RNAi Patents related to SARS/MERS
  • TABLE 6.8: (CONTINUED)
  • TABLE 6.8: (CONTINUED)
  • TABLE 7.1: Number of Clinical Trials for COVID-19 by Country/Region
  • TABLE 7.2: Number of Clinical Trials for COVID-19 by Study Type
  • TABLE 7.3: Drugs used as Pharmacological Interventions in COVID-19 Trials
  • TABLE 7.3: (CONTINUED)
  • TABLE 7.4: COVID-19 Clinical Trials by Stage of Development
  • TABLE 7.5: COVID-19 Clinical Studies by Funding Type
  • TABLE 7.6: Commercial Projects in Clinical Trials for COVID-19
  • TABLE 7.6: (CONTINUED)
  • TABLE 7.6: (CONTINUED)
  • TABLE 7.6: (CONTINUED)
  • TABLE 7.7: Upcoming Readouts from Ongoing COVID-19 Clinical Trials
  • TABLE 8.1: The Ten Most Affected Biotechs Due to COVID-19 Crisis
  • TABLE 8.2: Clinical Trial Terminations/Withdrawals/Suspensions
  • TABLE 8.3: Valuable R&D Assets under Threat of Delay Due to COVID-19
  • TABLE 8.4: Commercially Sponsored Pivotal Trials due to Readout by the end of 2020
  • TABLE 8.5: Phase III Trials facing Shortages of Patients due to COVID-19
  • TABLE 8.6: The Biggest Phase III Trials that are still searching for Patients
  • TABLE 8.7: Threat to Trials of Near-Term Blockbusters
  • TABLE 8.8: COVID-19 Infected Orthopedic Companies
  • TABLE 8.9: COVID-19-Infected Cardiovascular Firms
  • TABLE 8.10: Select Pending Acquisitions in Healthcare
  • TABLE 8.10: (CONTINUED)
  • TABLE 8.11: Select COVID-19 Deals and Collaborations
  • TABLE 8.11: (CONTINUED)
  • TABLE 8.12: Key COVID-19 Market Movers as of April 1, 2020
  • TABLE 8.13: COVID-19-Related Stock Risers
  • TABLE 9.1: Current Count on Emerging Treatments and Vaccines for COVID-19
  • TABLE 10.1: Types of Vaccines in Development
  • TABLE 10.1: Protein Sub-Unit Vaccines in Development against COVID-19
  • TABLE 10.1: (CONTINUED)
  • TABLE 10.1: (CONTINUED)
  • TABLE 10.1: (CONTINUED)
  • TABLE 10.1: (CONTINUED)
  • TABLE 10.1: (CONTINUED)
  • TABLE 10.1: (CONTINUED)
  • TABLE 10.2: RNA-Based Vaccines in Development for COVID-19
  • TABLE 10.2: (CONTINUED)
  • TABLE 10.2: (CONTINUED)
  • TABLE 10.2: (CONTINUED)
  • TABLE 10.3: Non-Replicating Viral Vector Vaccines in Development for COVID-19
  • TABLE 10.3: (CONTINUED)
  • TABLE 10.3: (CONTINUED)
  • TABLE 10.3: (CONTINUED)
  • TABLE 10.4: DNA Vaccines in Development for COVID-19
  • TABLE 10.4: (CONTINUED)
  • TABLE 10.5: Inactivated Virus Vaccines in Development for COVID-19
  • TABLE 10.6: Virus-like Particle Vaccines in Development for COVID-19
  • TABLE 10.6: (CONTINUED)
  • TABLE 10.7: Additional COVID-19 Vaccine Projects
  • TABLE 10.8: Cepi's Call for Funding
  • TABLE 10.9: Estimated Cost of Select Pandemic Clinical Programs
  • TABLE 10.10: Most Recent Collaborations in Vaccine Sector
  • TABLE 10.11: Select COVID-19 Vaccines with Big Pharma Involvement
  • TABLE 11.1: Antibody Drugs in Development for COVID-19
  • TABLE 11.1: (CONTINUED)
  • TABLE 11.1: (CONTINUED)
  • TABLE 11.1: (CONTINUED)
  • TABLE 11.1: (CONTINUED)
  • TABLE 11.1: (CONTINUED)
  • TABLE 11.1: (CONTINUED)
  • TABLE 11.1: (CONTINUED)
  • TABLE 11.1: (CONTINUED)
  • TABLE 11.1: (CONTINUED)
  • TABLE 11.1: (CONTINUED)
  • TABLE 12.1: Antiviral Drugs in Development for COVID-19
  • TABLE 12.1: (CONTINUED)
  • TABLE 12.1: (CONTINUED)
  • TABLE 12.1: (CONTINUED)
  • TABLE 12.1: (CONTINUED)
  • TABLE 12.2: Estimated Cost of COVID-19 Clinical Program (Remdesivir)
  • TABLE 12.3: Comparison of Remdesivir's Three Datasets
  • TABLE 12.4: Interim Data from Gilead's Trial (NCT04292899)
  • TABLE 12.5: Additional COVID-19 Therapeutic Projects
  • TABLE 13.1: Repurposed Drugs in Development for COVID-19
  • TABLE 13.1: (CONTINUED)
  • TABLE 13.1: (CONTINUED)
  • TABLE 13.1: (CONTINUED)
  • TABLE 14.1: Cell-Based Therapies in Development for COVID-19
  • TABLE 14.1: (CONTINUED)
  • TABLE 14.1: (CONTINUED)
  • TABLE 14.1: (CONTINUED)
  • TABLE 15.1: Medical Devices in Development for COVID-19
  • TABLE 15.1: (CONTINUED)
  • TABLE 15.2: Select Makers of Modifiable Devices Eligible for EUAs
  • TABLE 15.3: Number of FDA-Approved Ventilators between 2014 and 2020
  • TABLE 16.1: Accuracy Figures for Select COVID-19 Antibody Tests
  • TABLE 16.1: (CONTINUED)
  • TABLE 16.1: (CONTINUED)
  • TABLE 16.2: Accuracy Figures for Top Eight COVID-19 Antibody Tests
  • TABLE 16.3: Top Ten COVID-19 Diagnostic Companies
  • TABLE 16.4: Commercially Available COVID-19 Diagnostic Tests
  • TABLE 16.4: (CONTINUED)
  • TABLE 16.4: (CONTINUED)
  • TABLE 16.4: (CONTINUED)
  • TABLE 16.4: (CONTINUED)
  • TABLE 16.4: (CONTINUED)
  • TABLE 16.4: (CONTINUED)
  • TABLE 16.4: (CONTINUED)
  • TABLE 16.4: (CONTINUED)
  • TABLE 16.4: (CONTINUED)
  • TABLE 16.4: (CONTINUED)
  • TABLE 16.4: (CONTINUED)
  • TABLE 16.4: (CONTINUED)
  • TABLE 16.4: (CONTINUED)
  • TABLE 16.4: (CONTINUED)
  • TABLE 16.4: (CONTINUED)
  • TABLE 16.4: (CONTINUED)
  • TABLE 17.1: Estimated Global Market for COVID-19 Vaccines, 2020-2027
  • TABLE 17.2: Global Market for COVID-19 Drugs, 2020-2027
  • TABLE 17.3: Global Market for COVID-19 Testing Kits by Geography, 2020-2027
  • TABLE 17.4: Global Market for COVID-19 Testing Kits by Technology, 2020-2027
  • TABLE 17.5: COVID-19 Impacted Market for PPE Products, 2020-2027
  • TABLE 17.6: Estimated COVID-19 Addressable Critical Care Device Market, 2020-2027
  • TABLE 17.7: Global Market for "Other" COVID-19-Related Medical Supplies, 2020-2027
  • TABLE 17.8: Global Market for COVID-19 Treatment, 2020-2027
  • TABLE App. 1.1: A Timeline of Historical Pandemics
  • TABLE App. 1.1: (CONTINUED)
  • TABLE: App. 1.2: Ro Number of Pandemics
  • TABLE App. 2.1: Global Health Security Index Score
  • TABLE App. 2.1: (CONTINUED)
Back to Top